These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38248629)

  • 1. Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement.
    Lionel AC; Gurumurthi A; Fetooh A; Eldaya R; Ahmed S; Iyer SP; Nastoupil LJ; Westin J; Nair R; Fayad L; Malpica L; Tummala S; Flowers C; Neelapu SS; Wang ML; Jain P
    Leuk Lymphoma; 2024 May; 65(5):669-673. PubMed ID: 38248629
    [No Abstract]   [Full Text] [Related]  

  • 2. Combining forces for good: chimeric antigen receptor T-cells and Bruton tyrosine kinase inhibitors in mantle cell lymphoma with central nervous system involvement.
    Minson A; Dickinson M
    Leuk Lymphoma; 2024 May; 65(5):546-547. PubMed ID: 38420955
    [No Abstract]   [Full Text] [Related]  

  • 3. [New European Approvals: Brexucabtagene autoleucel for refractory mantle cell lymphoma after Bruton tyrosine kinase (BTK) inhibitor].
    Rousseau A; Thieblemont C
    Bull Cancer; 2021 Feb; 108(2):142-144. PubMed ID: 33531153
    [No Abstract]   [Full Text] [Related]  

  • 4. Management of relapsed/refractory mantle cell lymphoma.
    Alzahrani M; Villa D
    Leuk Lymphoma; 2024 Aug; 65(8):1044-1054. PubMed ID: 38635491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor.
    Salles G; Chen JMH; Zhang I; Kerbauy F; Wu JJ; Wade SW; Nunes A; Feng C; Kloos I; Peng W; Snider JT; Maciel D; Chan K; Keeping S; Shah B
    Adv Ther; 2024 May; 41(5):1938-1952. PubMed ID: 38494543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy.
    Jain P; Nastoupil L; Westin J; Lee HJ; Navsaria L; Steiner RE; Ahmed S; Moghrabi O; Oriabure O; Chen W; Badillo M; Flowers CR; Wang ML
    Br J Haematol; 2021 Jan; 192(2):e38-e42. PubMed ID: 33152104
    [No Abstract]   [Full Text] [Related]  

  • 7. BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma-Finding a Dancing Partner.
    Munoz JL; Wang Y; Jain P; Wang M
    Curr Oncol Rep; 2022 Oct; 24(10):1299-1311. PubMed ID: 35596920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brexucabtagene autoleucel: a breakthrough in the treatment of mantle cell lymphoma.
    Deshpande A; Wang Y; Munoz J; Jain P
    Drugs Today (Barc); 2022 Jun; 58(6):283-298. PubMed ID: 35670706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma.
    Iacoboni G; Rejeski K; Villacampa G; van Doesum JA; Chiappella A; Bonifazi F; Lopez-Corral L; van Aalderen M; Kwon M; Martínez-Cibrian N; Bramanti S; Reguera-Ortega JL; Camacho-Arteaga L; Schmidt C; Marín-Niebla A; Kersten MJ; Martin Garcia-Sancho A; Zinzani PL; Corradini P; van Meerten T; Subklewe M; Barba P
    Blood Adv; 2022 Jun; 6(12):3606-3610. PubMed ID: 35271707
    [No Abstract]   [Full Text] [Related]  

  • 10. CAR T-cell therapy in mantle cell lymphoma with secondary CNS involvement: a multicenter experience.
    Ahmed G; Alsouqi A; Szabo A; Samples L; Shadman M; Awan FT; Rojek AE; Riedell PA; Iqbal M; Fenske TS; Kharfan-Dabaja MA; Ito S; Hamadani M
    Blood Adv; 2024 Jul; 8(13):3528-3531. PubMed ID: 38701405
    [No Abstract]   [Full Text] [Related]  

  • 11. Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas.
    Reagan PM; Friedberg JW
    Future Oncol; 2021 Apr; 17(11):1269-1283. PubMed ID: 33448873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brexucabtagene Autoleucel: A Novel Chimeric Antigen Receptor T-cell Therapy for the Treatment of Mantle Cell Lymphoma.
    Anderson MK; Torosyan A; Halford Z
    Ann Pharmacother; 2022 May; 56(5):609-619. PubMed ID: 34340597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic options for relapsed/refractory mantle cell lymphoma.
    Eyre TA; Cheah CY; Wang ML
    Blood; 2022 Feb; 139(5):666-677. PubMed ID: 34679161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma (MCL) in the Era of CAR-T Cell Therapy?
    Beitinjaneh A; Kaufman A; Wang Y; Jain P; Srour SA; Wang M
    Curr Treat Options Oncol; 2022 Nov; 23(11):1614-1625. PubMed ID: 36227407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma.
    Marchetti M; Visco C
    Leuk Lymphoma; 2023; 64(8):1442-1450. PubMed ID: 37229538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
    Wang M; Munoz J; Goy A; Locke FL; Jacobson CA; Hill BT; Timmerman JM; Holmes H; Jaglowski S; Flinn IW; McSweeney PA; Miklos DB; Pagel JM; Kersten MJ; Milpied N; Fung H; Topp MS; Houot R; Beitinjaneh A; Peng W; Zheng L; Rossi JM; Jain RK; Rao AV; Reagan PM
    N Engl J Med; 2020 Apr; 382(14):1331-1342. PubMed ID: 32242358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging therapies in mantle cell lymphoma.
    Hanel W; Epperla N
    J Hematol Oncol; 2020 Jun; 13(1):79. PubMed ID: 32552760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma.
    Jiang VC; Liu Y; Jordan A; McIntosh J; Li Y; Che Y; Jessen KA; Lannutti BJ; Wang M
    J Hematol Oncol; 2021 Aug; 14(1):132. PubMed ID: 34454548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-BTK inhibitor mantle cell lymphoma: When is CAR-T not the answer?
    McCulloch R
    Br J Haematol; 2023 Aug; 202(4):718-719. PubMed ID: 37188352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of KTE-X19 CAR T therapy versus real-world standard of care in patients with relapsed/refractory mantle cell lymphoma post BTKi in England.
    Petersohn S; Salles G; Wang M; Wu J; Wade SW; Simons CL; Bennison C; Siddiqi R; Peng W; Kloos I; Castaigne G; Hess G
    J Med Econ; 2022; 25(1):730-740. PubMed ID: 35611697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.